Study of Pembrolizumab, Lenvatinib and Chemotherapy Combination in First Line Extensive-stage Small Cell Lung Cancer
Clinical trial NCT05384015 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05384015
- Sponsor
- Fundación GECP
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-11-07
- Primary completion
- 2027-07-30
- Enrollment
- 46
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.